These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21593750)

  • 1. Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?
    Kaul S; Diamond GA
    Clin Pharmacol Ther; 2011 Jun; 89(6):773-6. PubMed ID: 21593750
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    Schernthaner G; Chilton RJ
    Diabetes Obes Metab; 2010 Dec; 12(12):1023-35. PubMed ID: 20977573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rosiglitazone].
    Johansen K
    Ugeskr Laeger; 2010 Sep; 172(38):2631; author reply 2631. PubMed ID: 20931733
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 12. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
    Hernandez AV; Walker E; Ioannidis JP; Kattan MW
    Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment: Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Musini VM; Bassett KL; Tejani AM
    Ann Pharmacother; 2009 Feb; 43(2):391-2; author reply 392-3. PubMed ID: 19193598
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
    Marx N
    Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
    [No Abstract]   [Full Text] [Related]  

  • 16. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.
    Tan A; Cao Y; Xia N; Mo Z; Gao F
    Eur J Intern Med; 2010 Oct; 21(5):398-403. PubMed ID: 20816593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversy over the cardiovascular effects of thiazolidinediones.
    Kapoor JR
    Am J Med; 2008 Apr; 121(4):e9. PubMed ID: 18374677
    [No Abstract]   [Full Text] [Related]  

  • 19. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 20. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.
    George J; Hannah S; Lang CC
    Cardiovasc Ther; 2009; 27(2):83-8. PubMed ID: 19426244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.